225 results on '"Schlaak JF"'
Search Results
2. Hepatitis B virus activates toll-like receptor 2 signaling in primary human hepatocytes
3. IFN-α subtypes : Distinct biological activities in anti-viral therapy
4. Poly I:C-stimulated human non-parenchymal liver cells are potent suppressors of hepatitis C virus replication
5. Amphipathic, nucleic acid-based polymers optimized to treat hepatitis B virus infection in patients do not harbour immune stimulatory properties in primary isolated blood or liver cells
6. Erythropoetin verbessert die Leberregeneration bei Spender und Empfänger in einem Rattenmodell der Leberlebendtransplantation
7. Proteasome subunit alpha type-6 regulates the expression of proviral host genes in hepatitis C virus infection
8. Increased Lysyl oxidase-like 2 (LOXL2) gene expression accurately designates advanced liver fibrosis induced by the Hepatitis C Virus (HCV) regardless race, blood specimen or co-infection with the Human Immunodeficiency Virus (HIV)
9. All-In-One: Advanced human parenchymal and non-parenchymal liver cell preparation
10. Hepadnaviral replication in HBV-transgenic mice lacking the surface antigen (HBsAg) is controlled by toll-like receptor 3-induced immune responses
11. Dysregulation of innate immunity in hepatitis C virus genotype 1 IL28B-unfavorable genotype patients: Impaired viral kinetics and therapeutic response
12. Human non-parenchymal liver cells produce type I and type III interferons in response to poly I:C, thereby mediating an antiviral state against HCV
13. New mouse model mimicking IFN-related depression in HCV patients
14. Toll-like receptor 3 activation mediates the expression of interferon and interferon stimulated genes during hepadnaviral replication in HBV-transgenic mice lacking the HBs-antigen
15. Interferon stimulated gene 15, a proviral factor in hepatitis C virus replication, is regulated by the Proteasome subunit alpha type-6
16. KIR2DL3+ NKG2A- Natural Killer Cells Protect People who Inject Drugs against Productive Hepatitis C Virus Infection
17. Können wir CED und RDS immunologisch differenzieren?
18. Einfluss des Lebervenenausflusses auf die Regeneration und Funktion der Leber nach erweiterter Teilentfernung
19. Characterization and potential clinical implications of different subtypes of circulating tumor cells in patients with hepatocellular carcinoma
20. TLR stimulated human non-parenchymal liver cells are potent suppressors of HCV replication
21. Suppression of the interferon sensitive gene 15 affects the expression of proteins that play a role in HCV replication
22. IFNs and ISGs are up-regulated in HBV-transgenic mice lacking HBsAg
23. Interferon standard therapy alters neuronal physiology in HCV patients
24. Continuous Toll-like receptor 3 activation in primary human hepatocytes, mimicking chronic hepatitis C infection, leads to hyper-responsiveness to poly I:C in vitro
25. Activation by Pathogen- and Damage-Associated Molecular Patterns Regulates the Expression of RANTES in Primary Hepatic Stellate Cells
26. In vivo knockdown, mediated by LNP01-formulated siRNAs, of HCV pro-viral factor ISG15 increased responsiveness to Interferon
27. Hepatic, MyD88-dependent toll-like receptors are activated by in vivo application of LNP01-formulated siRNAs
28. Differential regulation of depression associated interferon-inducible genes identified in HCV patients during IFN-alpha therapy in hippocampal and prefrontal cortex mouse neurons
29. Interferon-alpha treatment differenzially modifies the expression of depression-related interferon-inducible genes in vivo and in vitro
30. Toll-like receptor-activated primary human hepatocytes produce inflammatory cytokines and different types of interferon, resulting in HCV suppression in a co-culture model
31. HCV/TLR3 modulated the expression of RANTES in murine activated hepatic stellate cells
32. In vivo treatment with nanolipid-formulated siRNAs targeting ISG15 leads to enhanced responsiveness to interferon in primary hepatocytes
33. Better detection of Hepatocellular Carcinoma by combining Alphafeto-Protein (AFP) and Des-Gamma-Carboxyprothrombin (DCP)
34. Presence of primary human hepatocytes inhibits expansion of virus-specific CD8+ T cells in vitro
35. Hepatic toll-like receptors can be activated by application of siRNAs in vivo via MyD88-dependent pathways which can be controlled by chemical ribose modifications of the siRNA backbone
36. Toll-like receptor-activated primary human hepatocytes produce inflammatory cytokines and different types of interferon, resulting in HCV suppression in vitro
37. All-trans retinoic acid co-administered with pegylated interferon and ribavirin does not influence viral kinetics in hepatitis C infected patients with previous non-response: Results of the ATRACTION study
38. The production of interferons is not impaired in primary isolated liver cells from HCV-positive individuals after Toll-like receptor mediated stimulation
39. The non-specific activation of liver tissue by siRNAs in vivo can be controlled by chemical ribose modifications of siRNAs
40. Nonalcoholic Fatty Liver Disease progresses to HCC in the absence of apparent Cirrhosis
41. Treatment of chronic hepatitis B with Telbivudine alone or in combination with nucleotide analogues
42. Correlation of type I, -II and -III interferon expression in the liver with clinical and viral parameters in chronic HCV infection
43. VEGF improves liver regeneration and survival after 90% hepatectomy in a rat model of fatty liver disease
44. The activation of the hepatic innate immune system by siRNA is controlled by chemical modifications and may involve endosomal Toll-like receptors
45. HBsAg is a potent suppressor of Toll-like receptor mediated innate and adaptive immune responses in liver cells and PBMC
46. HCV/TLR3-dependent innate and adaptive immune functions of non-parenchymal liver cells are controlled by interleukin-10 and transforming growth factor beta
47. Der NF-KB Inhibitor Bortezomib führt zu einer deutlich erhöhten Sterblichkeit nach Leberteilresektion
48. Selektive Hyper-Responsibilität des Interferonsystems im Gehirn von Patienten mit Hepatitis C und schwerer Depression
49. Das Interferon-sensitive Gen 15 (ISG15) hat eine provirale Funktion im Rahmen der Hepatitis C Virus Infektion
50. Treatment with the NF-κB inhibitor bortezomib leads to suppression of proregenerative cytokines and significant mortality after liver resection
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.